Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N, Matin SF, Pierorazio PM, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky S, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Stern J, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Adibi M, Amin MB, Seltzer E, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Schoenberg M, Lerner SP. Kleinmann N, et al. Among authors: godoy g. Lancet Oncol. 2020 Jun;21(6):776-785. doi: 10.1016/S1470-2045(20)30147-9. Epub 2020 Apr 29. Lancet Oncol. 2020. PMID: 32631491 Clinical Trial.
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Matin SF, et al. Among authors: godoy g. J Urol. 2022 Apr;207(4):779-788. doi: 10.1097/JU.0000000000002350. Epub 2021 Dec 17. J Urol. 2022. PMID: 34915741 Clinical Trial.
Reply by Authors.
Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Matin SF, et al. Among authors: godoy g. J Urol. 2022 Apr;207(4):788. doi: 10.1097/JU.0000000000002350.02. Epub 2022 Jan 4. J Urol. 2022. PMID: 34985341 No abstract available.
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF, Godoy G, Alva A, Hahn NM, Carducci MA, Hoffman-Censits J; Collaborators. Margulis V, et al. Among authors: godoy g. J Urol. 2020 Apr;203(4):690-698. doi: 10.1097/JU.0000000000000644. Epub 2019 Nov 8. J Urol. 2020. PMID: 31702432 Free PMC article. Clinical Trial.
Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.
Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M, Bochner BH, Coleman J, Dalbagni G. Favaretto RL, et al. Among authors: godoy g. BJU Int. 2012 Jan;109(1):77-82. doi: 10.1111/j.1464-410X.2011.10288.x. Epub 2011 Jun 1. BJU Int. 2012. PMID: 21631698 Free PMC article.
257 results